{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:26:47Z","timestamp":1792772807593,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU21-07-00189"],"award-info":[{"award-number":["NU21-07-00189"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["LRI CZECRIN (LM2023049)"],"award-info":[{"award-number":["LRI CZECRIN (LM2023049)"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40123-026-01506-x","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:12:32Z","timestamp":1791205952000},"page":"3851-3867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of 0.02% and 0.04% Atropine Therapy for Myopia Control in Czech Children: The MARS Trial"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7962-7783","authenticated-orcid":false,"given":"Martin","family":"Hlo\u017e\u00e1nek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-4998","authenticated-orcid":false,"given":"Miroslav","family":"Dost\u00e1lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2689-882X","authenticated-orcid":false,"given":"Rudolf","family":"Autrata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"\u0160t\u011bp\u00e1nov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana Unar","family":"Vinklerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2614-4681","authenticated-orcid":false,"given":"Jarmila","family":"Heissigerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-4074","authenticated-orcid":false,"given":"Pavel","family":"Studen\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"\u010c\u00e1slavsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Je\u0159\u00e1bkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4445-6072","authenticated-orcid":false,"given":"Nina","family":"Zelenayov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3975-3830","authenticated-orcid":false,"given":"Inka","family":"Krej\u010d\u00ed\u0159ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1ta","family":"Brunnerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-9463","authenticated-orcid":false,"given":"Marta","family":"Korbasov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8322-5165","authenticated-orcid":false,"given":"Martin","family":"Kom\u00ednek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"5","key":"1506_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2000","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2000;123(5):1036\u201342.","journal-title":"Ophthalmology"},{"key":"1506_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101319","volume":"54","author":"A Moreira-Rosario","year":"2025","unstructured":"Moreira-Rosario A, Lanca C, Grzybowski A. Prevalence of myopia in Europe: a systematic review and meta-analysis of data from 14 countries. Lancet Reg Health Eur. 2025;54:101319.","journal-title":"Lancet Reg Health Eur"},{"issue":"7","key":"1506_CR3","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s40123-026-01412-2","volume":"15","author":"C Lanca","year":"2026","unstructured":"Lanca C, Morgan I, Grzybowski A. Myopia trends in Europe: a reappraisal of current evidence. Ophthalmol Ther. 2026;15(7):2107\u201315.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"1506_CR4","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"1506_CR5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","volume":"128","author":"MA Bullimore","year":"2021","unstructured":"Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RRA, Flitcroft DI. The risks and benefits of myopia control. Ophthalmology. 2021;128(11):1561\u201379.","journal-title":"Ophthalmology"},{"key":"1506_CR6","doi-asserted-by":"crossref","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113\u201324.","DOI":"10.1016\/j.ophtha.2018.05.029"},{"issue":"3","key":"1506_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","volume":"104","author":"CSY Lam","year":"2020","unstructured":"Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"1506_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jamaophthalmol.2022.0401","volume":"140","author":"J Bao","year":"2022","unstructured":"Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, et al. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA Ophthalmol. 2022;140(5):472\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"1506_CR9","volume":"1","author":"JJ Walline","year":"2020","unstructured":"Walline JJ, Lindsley KB, Vedula SS, Cotter SA, Mutti DO, Ng SM, et al. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 2020;1:CD004916.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1506_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","volume":"129","author":"A Ha","year":"2022","unstructured":"Ha A, Kim SJ, Shim SR, Kim YK, Jung JH. Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis. Ophthalmology. 2022;129(3):322\u201333.","journal-title":"Ophthalmology"},{"key":"1506_CR11","volume-title":"Cochrane Database of Systematic Reviews","author":"JG Lawrenson","year":"2023","unstructured":"Lawrenson JG, Shah R, Huntjens B, Downie LE, Virgili G, Dhakal R, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis (Review). In: Collaboration C, editor., et al., Cochrane Database of Systematic Reviews. London: Cochrane Library; 2023."},{"issue":"5","key":"1506_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/bjo-2025-328518","volume":"110","author":"S Biswas","year":"2026","unstructured":"Biswas S, Lanca C, Kynman-Sprinks D, Grzybowski A. Ethnic and dose-dependent differences in atropine efficacy for myopia control: a systematic review and meta-analysis. Br J Ophthalmol. 2026;110(5):483\u201391.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1506_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jamaophthalmol.2024.5703","volume":"143","author":"J Loughman","year":"2025","unstructured":"Loughman J, Lingham G, Nkansah EK, Kobia-Acquah E, Flitcroft DI. Efficacy and safety of different atropine regimens for the treatment of myopia in children: three-year results of the MOSAIC randomized clinical trial. JAMA Ophthalmol. 2025;143(2):134\u201344.","journal-title":"JAMA Ophthalmol"},{"key":"1506_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-086698","volume":"393","author":"A Azuara-Blanco","year":"2026","unstructured":"Azuara-Blanco A, Logan NS, McConnell E, Kearney S, Kirk G, Jones S, et al. Low concentration atropine eye drops and progression of myopia in children: multicentre placebo controlled, double masked, randomised trial in the UK (CHAMP-UK). BMJ. 2026;393:e086698.","journal-title":"BMJ"},{"key":"1506_CR15","doi-asserted-by":"crossref","unstructured":"Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. 2023;141(8):756\u201365.","DOI":"10.1001\/jamaophthalmol.2023.2855"},{"key":"1506_CR16","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"},{"issue":"3","key":"1506_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1506_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"3","key":"1506_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/aos.13603","volume":"96","author":"JWL Tideman","year":"2018","unstructured":"Tideman JWL, Polling JR, Vingerling JR, Jaddoe VWV, Williams C, Guggenheim JA, et al. Axial length growth and the risk of developing myopia in European children. Acta Ophthalmol. 2018;96(3):301\u20139.","journal-title":"Acta Ophthalmol"},{"key":"1506_CR20","doi-asserted-by":"publisher","unstructured":"Hvid-Hansen A, Jacobsen N, M\u00f8ller F, Bek T, Ozenne B, Kessel L. Myopia control with low-dose atropine in european children: six-month results from a randomized, double-masked, placebo-controlled, multicenter study. J Pers Med. 2023;13(2):325. https:\/\/doi.org\/10.3390\/jpm13020325.","DOI":"10.3390\/jpm13020325"},{"key":"1506_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60071022","author":"D Simonaviciute","year":"2024","unstructured":"Simonaviciute D, Gelzinis A, Kapitanovaite L, Grzybowski A, Zemaitiene R. Myopia control in Caucasian children with 0.01% atropine eye drops: 1-year follow-up study. Medicina (Kaunas). 2024. https:\/\/doi.org\/10.3390\/medicina60071022.","journal-title":"Medicina (Kaunas)"},{"key":"1506_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113218","author":"D Simonaviciute","year":"2024","unstructured":"Simonaviciute D, Grzybowski A, Gelzinis A, Zemaitiene R. Efficacy and safety of 0.03% atropine eye drops in controlling myopia progression: a one-year prospective clinical study. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13113218.","journal-title":"J Clin Med"},{"key":"1506_CR23","doi-asserted-by":"crossref","unstructured":"Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Macley DA, et al. Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2024;102(3):e245\u2013e256.","DOI":"10.1111\/aos.15761"},{"key":"1506_CR24","doi-asserted-by":"publisher","unstructured":"Dost\u00e1lek M, Zajdl\u00edkov\u00e1 B, Kom\u00ednek M, Krej\u010d\u00ed\u0159ov\u00e1 I, Heissigerov\u00e1 J, Autrata R, et al. Evaluation of accommodation and pupillary reaction in children with myopia treated by highly diluted atropine in the MARS trial. J Clin Case Stud Rev Rep. 2024;6:327. https:\/\/doi.org\/10.47363\/JCCSR\/2024(6)327.","DOI":"10.47363\/JCCSR\/2024(6)327"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01506-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:46:07Z","timestamp":1792763167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01506-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01506-x","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"20 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Martin Hlo\u017e\u00e1nek, Miroslav Dost\u00e1lek, Rudolf Autrata, Radka \u0160t\u011bp\u00e1nov\u00e1, Jana Unar Vinklerov\u00e1, Pavel Studen\u00fd, Barbora \u010c\u00e1slavsk\u00e1, Lucie Je\u0159\u00e1bkov\u00e1, Nina Zelenayov\u00e1, Inka Krej\u010d\u00ed\u0159ov\u00e1, Ren\u00e1ta Brunnerov\u00e1, Marta Korbasov\u00e1, and Martin Kom\u00ednek have nothing to disclose. Jarmila Heissigerov\u00e1 is an editorial board member of Ophthalmology and Therapy. Jarmila Heissigerov\u00e1 was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Multicentric Ethics Committee of University Hospital Brno (72\/20MEK) and the local ethics committees of General University Hospital, Prague (1930\/20 S); University Hospital Motol and Homolka, Prague (EK-1395\/20); University Hospital Kr\u00e1lovsk\u00e9 Vinohrady, Prague (EK-VP\/23\/01\/2020); and Litomy\u0161l Hospital (Studie Binocular 2020\/1). The study was conducted in accordance with the Declaration of Helsinki and ICH-GCP. Written informed consent was obtained from parents or legal guardians, with age-appropriate assent from participants.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}